This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabri, O. Articles by Buell, U. Search for Related Content PubMed PubMed Citation Articles by Sabri, O. Articles by Buell, U.

Success Rate of Radioiodine Therapy in Graves’ Disease: The Influence of Thyrostatic Medication

Departments of Nuclear Medicine and Neuropsychology (K.W.), Aachen University of Technology, Aachen, Germany

Address all correspondence and requests for reprints to: O. Sabri, Ph.D., M.D., Department of Nuclear Medicine, Aachen University of Technology, Pauwelsstrasse 30, D-52057 Aachen, Germany.

There is controversy whether simultaneous thyrostatic medication influences the outcome of radioiodine (¹³¹I) therapy in Graves’ disease by reducing the absorbed energy dose of ¹³¹I when delivering a standard dose. We therefore sought to ascertain whether the outcome of ablative ¹³¹I therapy is in any way affected by simultaneous thyrostasis (carbimazole) by aiming for a constant absorbed dose of 200–250 Gy. We prospectively studied 207 patients with Graves’ disease (106 with and 101 without simultaneous carbimazole at the time of ¹³¹I therapy). All patients were reexamined 3, 6, and 12 months after ¹³¹I therapy. The 101 nonthyrostatic patients showed a highly significantly greater success rate (93%) than the 106 thyrostatic patients (49%). Stepwise logistic regression demonstrated that failure was related to the administration of carbimazole during ¹³¹I therapy (P < 0.00005) and the absorbed dose (P < 0.025), but was not related to free T₃, free T₄, TSH receptor antibodies, or thyroid volume. The success rate was 100% in 93 nonthyrostatic patients with absorbed doses of 200 Gy or more, but was only 12.5% (1 of 8) for absorbed doses less than 200 Gy. Correlation between success and absorbed dose was significantly higher for nonthyrostatic than for thyrostatic patients (r = 0.93 vs. r = 0.24). Sixteen patients who discontinued thyrostasis 1–3 days before ¹³¹I therapy showed 94% successes.

Simultaneous thyrostasis is the decisive factor against a successful ¹³¹I therapy even if the significantly reduced ¹³¹I uptake/half-life values under thyrostasis are compensated with a higher delivered dose to ensure a comparable absorbed dose, possibly due to the additionally effective radioprotective properties of carbimazole. Therefore, if clinically feasible, we recommend discontinuing thyrostasis at least 1 day before beginning ¹³¹I therapy, because even in hyperthyroid nonthyrostatic patients the success rate was 100%.

This article has been cited by other articles:

				V. Markovic and D. Eterovic Thyroid Echogenicity Predicts Outcome of Radioiodine Therapy in Patients with Graves' Disease J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3547 - 3552. [Abstract] [Full Text] [PDF]

				M. A Walter, M. Briel, M. Christ-Crain, S. J Bonnema, J. Connell, D. S Cooper, H. C Bucher, J. Muller-Brand, and B. Muller Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials BMJ, March 10, 2007; 334(7592): 514 - 514. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, F. N. Bennedbaek, A. Veje, J. Marving, and L. Hegedus Continuous Methimazole Therapy and Its Effect on the Cure Rate of Hyperthyroidism Using Radioactive Iodine: An Evaluation by a Randomized Trial J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2946 - 2951. [Abstract] [Full Text] [PDF]

				Radioiodine therapy for hyperthyroidism DTB, June 1, 2006; 44(6): 44 - 48. [Abstract] [Full Text] [PDF]

				B. E Jensen, S. J Bonnema, and L. Hegedus Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease Eur. J. Endocrinol., July 1, 2005; 153(1): 15 - 21. [Abstract] [Full Text] [PDF]

				D. D Streetman and U. Khanderia Diagnosis and Treatment of Graves Disease Ann. Pharmacother., July 1, 2003; 37(7): 1100 - 1109. [Abstract] [Full Text] [PDF]

				F. Bogazzi, L. Bartalena, A. Campomori, S. Brogioni, C. Traino, F. De Martino, G. Rossi, F. Lippi, A. Pinchera, and E. Martino Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves' Disease J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4490 - 4495. [Abstract] [Full Text] [PDF]

				V. A. Andrade, J. L. Gross, and A. L. Maia The Effect of Methimazole Pretreatment on the Efficacy of Radioactive Iodine Therapy in Graves' Hyperthyroidism: One-Year Follow-Up of a Prospective, Randomized Study J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3488 - 3493. [Abstract] [Full Text] [PDF]

				A. Allahabadia, J. Daykin, M. C. Sheppard, S. C. L. Gough, and J. A. Franklyn Radioiodine Treatment of Hyperthyroidism--Prognostic Factors for Outcome J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3611 - 3617. [Abstract] [Full Text] [PDF]

				H. B. Burch, B. L. Solomon, D. S. Cooper, P. Ferguson, N. Walpert, and R. Howard The Effect of Antithyroid Drug Pretreatment on Acute Changes in Thyroid Hormone Levels after 131I Ablation for Graves' Disease J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3016 - 3021. [Abstract] [Full Text] [PDF]

				A. Allahabadia, J. Daykin, R. L. Holder, M. C. Sheppard, S. C. L. Gough, and J. A. Franklyn Age and Gender Predict the Outcome of Treatment for Graves' Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1038 - 1042. [Abstract] [Full Text]